471 related articles for article (PubMed ID: 8033109)
1. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP.
Sartorius CA; Groshong SD; Miller LA; Powell RL; Tung L; Takimoto GS; Horwitz KB
Cancer Res; 1994 Jul; 54(14):3868-77. PubMed ID: 8033109
[TBL] [Abstract][Full Text] [Related]
2. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of mixed properties of RU486 in progesterone receptor (PR)-transfected MDA-MB-231 cells: a model for studying the functions of progesterone analogues.
Lin VC; Aw SE; Ng EH; Ng EH; Tan MG
Br J Cancer; 2001 Dec; 85(12):1978-86. PubMed ID: 11747343
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: characterization of an assay in breast cancer cell lines.
Graham ML; Bunn PA; Jewett PB; Gonzalez-Aller C; Horwitz KB
Cancer Res; 1989 Jul; 49(14):3934-42. PubMed ID: 2736533
[TBL] [Abstract][Full Text] [Related]
5. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP.
Sartorius CA; Tung L; Takimoto GS; Horwitz KB
J Biol Chem; 1993 May; 268(13):9262-6. PubMed ID: 8387487
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical localization of progesterone receptors in breast cancer with anti-human receptor monoclonal antibodies.
Elashry-Stowers D; Zava DT; Speers WC; Edwards DP
Cancer Res; 1988 Nov; 48(22):6462-74. PubMed ID: 3180062
[TBL] [Abstract][Full Text] [Related]
7. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
8. Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines.
Cappelletti V; Miodini P; Fioravanti L; Di Fronzo G
Anticancer Res; 1995; 15(6B):2551-5. PubMed ID: 8669822
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: analysis of breast cancer cell mixtures and genetic instability of the T47D line.
Graham ML; Dalquist KE; Horwitz KB
Cancer Res; 1989 Jul; 49(14):3943-9. PubMed ID: 2660983
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the existence of a third progesterone receptor protein in human breast cancer cell line T47D.
Wei LL; Miner R
Cancer Res; 1994 Jan; 54(2):340-3. PubMed ID: 8275464
[TBL] [Abstract][Full Text] [Related]
11. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors.
Tung L; Mohamed MK; Hoeffler JP; Takimoto GS; Horwitz KB
Mol Endocrinol; 1993 Oct; 7(10):1256-65. PubMed ID: 8123133
[TBL] [Abstract][Full Text] [Related]
12. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins.
Sumida T; Itahana Y; Hamakawa H; Desprez PY
Cancer Res; 2004 Nov; 64(21):7886-92. PubMed ID: 15520195
[TBL] [Abstract][Full Text] [Related]
13. Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2.
Cui X; Lazard Z; Zhang P; Hopp TA; Lee AV
Oncogene; 2003 Oct; 22(44):6937-41. PubMed ID: 14534541
[TBL] [Abstract][Full Text] [Related]
14. Immunofluorescent localization of a novel progesterone receptor(s) in a T47D-Y breast cancer cell line lacking genomic progesterone receptor expression.
Price TM; Hansen EL; Oliver TN
J Soc Gynecol Investig; 2005 Dec; 12(8):610-6. PubMed ID: 16325750
[TBL] [Abstract][Full Text] [Related]
15. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells.
Klein-Hitpass L; Cato AC; Henderson D; Ryffel GU
Nucleic Acids Res; 1991 Mar; 19(6):1227-34. PubMed ID: 2030942
[TBL] [Abstract][Full Text] [Related]
16. An amino-terminal truncated progesterone receptor isoform, PRc, enhances progestin-induced transcriptional activity.
Wei LL; Hawkins P; Baker C; Norris B; Sheridan PL; Quinn PG
Mol Endocrinol; 1996 Nov; 10(11):1379-87. PubMed ID: 8923464
[TBL] [Abstract][Full Text] [Related]
17. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways.
Beck CA; Weigel NL; Moyer ML; Nordeen SK; Edwards DP
Proc Natl Acad Sci U S A; 1993 May; 90(10):4441-5. PubMed ID: 8389450
[TBL] [Abstract][Full Text] [Related]
18. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.
Dai D; Kumar NS; Wolf DM; Leslie KK
Am J Obstet Gynecol; 2001 Apr; 184(5):790-7. PubMed ID: 11303185
[TBL] [Abstract][Full Text] [Related]
19. Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer.
Lai J; Myers SA; Lawrence MG; Odorico DM; Clements JA
Mol Cancer Res; 2009 Jan; 7(1):129-41. PubMed ID: 19147544
[TBL] [Abstract][Full Text] [Related]
20. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA.
Lin VC; Ng EH; Aw SE; Tan MG; Ng EH; Chan VS; Ho GH
Clin Cancer Res; 1999 Feb; 5(2):395-403. PubMed ID: 10037189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
